Inqovi for AML treatment ...

Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...

Panelists discuss how implementing oral regimens faces significant operational barriers including formulary restrictions, prior authorization requirements, insurance coverage differences between ...

Please provide your email address to receive an email when new articles are posted on . Patients with AML who had a low ACS10 genetics score had worse survival outcomes than those with a high score.

Kura Oncology holds a strong cash position with Komzifti FDA approval and frontline AML expansion potential. Read why KURA ...

Analysis of 2823 adult patients with acute myeloid leukemia (AML) revealed that overall survival decreases almost linearly with increasing age across all European LeukemiaNet (ELN) genetic-risk groups ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Given the biological complexity of acute ...

AML is a fast-growing cancer of the blood and bone marrow that disproportionately affects older adults. Historically, age has been a key factor in determining treatment intensity, eligibility for ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...